AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27819170 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide (LEF) combined with prednisone
Number of subjects: 52
Study 27819170 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (CTX) combined with prednisone
Number of subjects: 52
Study 27819170 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (LEF and CTX)
Number of subjects: 52
Study 24292995 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 0
Study 24292995 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 0
Study 24292995 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 0
Study 22932264 — intervention group
Group type: EXPERIMENTAL
Intervention: Freehand (FH) inner cavity of bone
Number of subjects: 47
Study 22932264 — intervention group
Group type: COMPARATOR
Intervention: Whole bone (WB)
Number of subjects: 47
Study 22932264 — intervention group
Group type: EXPERIMENTAL
Intervention: Freehand (FH) whole pelvis V(40) ≥ 40%
Number of subjects: 47
Study 22932264 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher than grade 2 hematological toxicities
Number of subjects: 47
Study 21298835 — intervention group
Group type: EXPERIMENTAL
Intervention: Packed rice-oral rehydration solution (R-ORS)
Number of subjects: 70
Study 21298835 — intervention group
Group type: COMPARATOR
Intervention: Glucose-based oral rehydration solution (G-ORS)
Number of subjects: 70
Study 17621994 — intervention group
Group type: EXPERIMENTAL
Intervention: Soyfem (standardized isoflavones extract) 52-104 mg/24h, administered as 1 or 2 tablets twice a day
Number of subjects: 169
Study 17615482 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy massage with 3% grapefruit oil, cypress, and three other kinds of oil
Number of subjects: 0
Study 17615482 — intervention group
Group type: COMPARATOR
Intervention: Grapeseed oil (Control)
Number of subjects: 0
Study 14630848 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal-on-metal articulation
Number of subjects: 100
Study 14630848 — intervention group
Group type: COMPARATOR
Intervention: Ceramic-on-polyethylene bearing
Number of subjects: 100
Study 10870150 — intervention group
Group type: EXPERIMENTAL
Intervention: Outer Table method (group A)
Number of subjects: 60
Study 10870150 — intervention group
Group type: COMPARATOR
Intervention: Intracortical method (group B)
Number of subjects: 60
Study 9147572 — intervention group
Group type: EXPERIMENTAL
Intervention: Group techniques and relaxation
Number of subjects: 32
Study 9147572 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 8267064 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibroacoustic stimulation
Number of subjects: 48
Study 8267064 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study 3890640 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiacetazone plus isoniazid in the continuation phase
Number of subjects: 419
Study 3890640 — intervention group
Group type: COMPARATOR
Intervention: Isoniazid alone in the continuation phase
Number of subjects: 419
Study 3890640 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial phase of chemotherapy (streptomycin, isoniazid, rifampicin, and pyrazinamide)
Number of subjects: 419
Study 3890640 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation phase of chemotherapy
Number of subjects: 419
Study 30770334 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleaching with 37.5% hydrogen peroxide and desensitizing with 6.0% potassium nitrate, etching for 15 seconds (Group 2)
Number of subjects: 100
Study 30770334 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleaching with 37.5% hydrogen peroxide and desensitizing with 6.0% potassium nitrate, etching for 15 seconds (Group 3)
Number of subjects: 100
Study 30770334 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser irradiation and etching (Group 4)
Number of subjects: 100
Study 30770334 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandblasting and etching (Group 5)
Number of subjects: 100
Study 30102627 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 42
Study 30102627 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine IR
Number of subjects: 42
Study 26998705 — intervention group
Group type: EXPERIMENTAL
Intervention: Control-Intervention (CI) group received hourly alerts to get up during work hours
Number of subjects: 44
Study 26998705 — intervention group
Group type: COMPARATOR
Intervention: Control-Control (CC) group maintained normal behaviors
Number of subjects: 44
Study 24501164 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA® cream
Number of subjects: 216
Study 24501164 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 216
Study 22223819 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (4 weekly infusions of 375 mg/m(2))
Number of subjects: 60
Study 22223819 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 60
Study 19789832 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group with vibration (VTG)
Number of subjects: 151
Study 19789832 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (TG)
Number of subjects: 151
Study 19789832 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 151
Study 19192455 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (36 mg/day, 54 mg/day, 72 mg/day, 90 mg/day)
Number of subjects: 23
Study 19192455 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (maximally effective dose)
Number of subjects: 23
Study 19192455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 19192455 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS methylphenidate
Number of subjects: 23
Study 16187870 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear-relevant targets (snakes and spiders)
Number of subjects: 24
Study 16187870 — intervention group
Group type: EXPERIMENTAL
Intervention: Gray-scale version of the search arrays
Number of subjects: 24
Study 16187870 — intervention group
Group type: EXPERIMENTAL
Intervention: 1st interbeat interval (IBI) after search array onset
Number of subjects: 24
Study 16187870 — intervention group
Group type: EXPERIMENTAL
Intervention: 2nd interbeat interval (IBI)
Number of subjects: 24
Study 12356630 — intervention group
Group type: EXPERIMENTAL
Intervention: BQ‐123 (selective blocker of ET(A) receptors)
Number of subjects: 15
Study 12356630 — intervention group
Group type: EXPERIMENTAL
Intervention: ET‐1 (exogenous infusion)
Number of subjects: 15
Study 12356630 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 15
Study 12356630 — intervention group
Group type: EXPERIMENTAL
Intervention: BQ‐123 and BQ‐788 (coinfusion of selective blockers of ET(A) and ET(B) receptors)
Number of subjects: 15
Study 10471426 — intervention group
Group type: EXPERIMENTAL
Intervention: Remacemide hydrochloride 100 mg BID (2 intravenous infusions followed by 6 days' oral treatment)
Number of subjects: 8
Study 10471426 — intervention group
Group type: EXPERIMENTAL
Intervention: Remacemide hydrochloride 200 mg BID or higher
Number of subjects: 8
Study 10471426 — intervention group
Group type: EXPERIMENTAL
Intervention: Remacemide hydrochloride 400 mg BID
Number of subjects: 8
Study 10471426 — intervention group
Group type: EXPERIMENTAL
Intervention: Remacemide hydrochloride 500 mg BID
Number of subjects: 8
Study 10471426 — intervention group
Group type: EXPERIMENTAL
Intervention: Remacemide hydrochloride 600 mg BID
Number of subjects: 8
Study 10471426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8938005 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertically oriented frames with horizontally slanted texture gradients
Number of subjects: 4
Study 8938005 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontally oriented frames with vertically slanted texture gradients
Number of subjects: 4
Study 8938005 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of frame aspect ratio and pictorial depth
Number of subjects: 4
Study 1812773 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihistamines
Number of subjects: 168
Study 1812773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 6362340 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral digoxin
Number of subjects: 41
Study 6362340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 31553228 — intervention group
Group type: EXPERIMENTAL
Intervention: Toutongning (TTN) capsule (1200 mg, three times daily)
Number of subjects: 400
Study 31553228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 29652666 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention program (dietary advice, physical activity sessions, psychological counseling for parents)
Number of subjects: 75
Study 29652666 — intervention group
Group type: COMPARATOR
Intervention: Standard care program (visits to pediatrician, information on healthy lifestyle)
Number of subjects: 75
Study 26817912 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine plus oxaliplatin (capecitabine 1000 mg/m bid on days 1-10 and oxaliplatin 85 mg/m on day 1, every 2 weeks) followed by docetaxel plus capecitabine (docetaxel 30 mg/m on days 1 and 8, capecitabine 825 mg/m bid on days 1-14, every 3 weeks)
Number of subjects: 51
Study 26817912 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery after chemotherapy
Number of subjects: 51
Study 24170221 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone
Number of subjects: 348
Study 24170221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 348
Study 22241923 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab and low-dose transpupillary thermotherapy (TTT)
Number of subjects: 100
Study 22241923 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal ranibizumab and sham TTT
Number of subjects: 100
Study 22241923 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab and low-dose TTT
Number of subjects: 100
Study 20631453 — intervention group
Group type: EXPERIMENTAL
Intervention: iv cibenzoline (70 mg)
Number of subjects: 118
Study 20631453 — intervention group
Group type: COMPARATOR
Intervention: iv disopyramide (50 mg)
Number of subjects: 118
Study 20631453 — intervention group
Group type: EXPERIMENTAL
Intervention: iv cibenzoline
Number of subjects: 118
Study 17980189 — intervention group
Group type: EXPERIMENTAL
Intervention: CT plus RT
Number of subjects: 369
Study 17980189 — intervention group
Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 369
Study 15907672 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (antibiotics, corticosteroids, 0.9% sodium chloride solution, local decongestants, n=21)
Number of subjects: 65
Study 15907672 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (n=21)
Number of subjects: 65
Study 15907672 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese acupuncture (n=25)
Number of subjects: 65
Study 15907672 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal acupuncture at non-acupoints (n=19)
Number of subjects: 65
Study 12021223 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary stenting (group 2)
Number of subjects: 26
Study 12021223 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 1)
Number of subjects: 26
Study 12021223 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin
Number of subjects: 26
Study 10180750 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (FLU) administered intravenously
Number of subjects: 0
Study 10180750 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B (AMB) administered intravenously
Number of subjects: 0
Study 10180750 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (FLU) administered intravenously for 7 days then orally
Number of subjects: 0
Study 8579266 — intervention group
Group type: EXPERIMENTAL
Intervention: Sure-Closure device
Number of subjects: 40
Study 8579266 — intervention group
Group type: COMPARATOR
Intervention: Conventional wound closure methods (skin grafts and flaps)
Number of subjects: 40
Study 2651177 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg pirprofen capsules
Number of subjects: 40
Study 2651177 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 40
Study 131576 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoxamine (0-1%)
Number of subjects: 0
Study 131576 — intervention group
Group type: COMPARATOR
Intervention: Ephedrine (5%)
Number of subjects: 0
Study 131576 — intervention group
Group type: COMPARATOR
Intervention: Homatropine (0-5%)
Number of subjects: 0
Study 31005674 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Weight eating disorder/obesity prevention program
Number of subjects: 364
Study 31005674 — intervention group
Group type: EXPERIMENTAL
Intervention: Project Health eating disorder/obesity prevention program
Number of subjects: 364
Study 31005674 — intervention group
Group type: COMPARATOR
Intervention: Educational video condition
Number of subjects: 364
Study 27815771 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent inpatient program (4+4 days) consisting of Acceptance and Commitment Therapy, physical training, and work-related problem-solving.
Number of subjects: 168
Study 27815771 — intervention group
Group type: COMPARATOR
Intervention: Outpatient program (6 sessions during 6 weeks) primarily consisting of Acceptance and Commitment Therapy.
Number of subjects: 168
Study 25077662 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized exercise training (3 times per week for 12 weeks)
Number of subjects: 56
Study 25077662 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual (control group)
Number of subjects: 56
Study 23562150 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient self-ratings
Number of subjects: 0
Study 23562150 — intervention group
Group type: COMPARATOR
Intervention: Site-based ratings
Number of subjects: 0
Study 23562150 — intervention group
Group type: COMPARATOR
Intervention: Centralized ratings
Number of subjects: 0
Study 21189151 — intervention group
Group type: EXPERIMENTAL
Intervention: FSC 250/50 micrograms
Number of subjects: 621
Study 21189151 — intervention group
Group type: COMPARATOR
Intervention: FP 250 micrograms
Number of subjects: 621
Study 20155594 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 75
Study 20155594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 16723540 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile stimulation at 1, 4, or 10 Hz for 25 s blocks
Number of subjects: 10
Study 15604847 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents
Number of subjects: 0
Study 15604847 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 0
Study 15881479 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 0.5% ophthalmic solution
Number of subjects: 25
Study 15881479 — intervention group
Group type: COMPARATOR
Intervention: Gatifloxacin 0.3% ophthalmic solution
Number of subjects: 25
Study 10214566 — intervention group
Group type: EXPERIMENTAL
Intervention: ADCON-L
Number of subjects: 521
Study 10214566 — intervention group
Group type: COMPARATOR
Intervention: Surgical procedure without ADCON-L (Control)
Number of subjects: 521
Study 7717485 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine 0.5 mg.kg‐1
Number of subjects: 60
Study 7717485 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine 1 mg.kg‐1
Number of subjects: 60
Study 7717485 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 60
Study 2143882 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.33 mm (29-gauge) spinal needle
Number of subjects: 80
Study 2143882 — intervention group
Group type: COMPARATOR
Intervention: 0.52 mm (25-gauge) spinal needle
Number of subjects: 80
Study 2143882 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 6458456 — intervention group
Group type: EXPERIMENTAL
Intervention: Vleminckx mask
Number of subjects: 0
Study 6458456 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (mask vehicle)
Number of subjects: 0
Study 31812307 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin spray 2% for 8 weeks
Number of subjects: 160
Study 31812307 — intervention group
Group type: COMPARATOR
Intervention: Control group (age- and sex-matched)
Number of subjects: 160
Study 31812307 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin spray 2%
Number of subjects: 160
Study 27909084 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 phone-based motivational interviewing (MI) sessions (n = 107)
Number of subjects: 216
Study 27909084 — intervention group
Group type: COMPARATOR
Intervention: 6 sessions of FM self-management instructions (attention control, AC) (n = 109)
Number of subjects: 216
Study 27282374 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical prediction model combining sociodemographic and psychological variables
Number of subjects: 383
Study 27282374 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model performance
Number of subjects: 383
Study 24368558 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid stenting
Number of subjects: 231
Study 24368558 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy
Number of subjects: 231
Study 22575589 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (48 Gy in 20 fractions)
Number of subjects: 217
Study 22575589 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 217
Study 22575589 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Number of subjects: 217
Study 20716340 — intervention group
Group type: EXPERIMENTAL
Intervention: hnRNP A1
Number of subjects: 0
Study 20716340 — intervention group
Group type: EXPERIMENTAL
Intervention: hnRNP A3
Number of subjects: 0
Study 20716340 — intervention group
Group type: EXPERIMENTAL
Intervention: hnRNP A2/B1
Number of subjects: 0
Study 20716340 — intervention group
Group type: EXPERIMENTAL
Intervention: ASF/SF2
Number of subjects: 0
Study 20716340 — intervention group
Group type: EXPERIMENTAL
Intervention: A2/B1
Number of subjects: 0
Study 17931471 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved brochure versions with pictorials, tabs, and colour coding
Number of subjects: 100
Study 17931471 — intervention group
Group type: COMPARATOR
Intervention: Original brochure
Number of subjects: 100
Study 15383007 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprosartan (600 mg)
Number of subjects: 16
Study 15383007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 12220747 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centred approach
Number of subjects: 110
Study 12220747 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment from family physician
Number of subjects: 110
Study 9473850 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplitude-modulated breathing technique
Number of subjects: 10
Study 9473850 — intervention group
Group type: COMPARATOR
Intervention: Previous techniques (broadband respiration and metronomic breathing)
Number of subjects: 10
Study 8560162 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-aspartyl-glutamic acid (NAAGA) nasal spray, one puff per nostril, four times daily, for 3 weeks
Number of subjects: 66
Study 8560162 — intervention group
Group type: COMPARATOR
Intervention: Disodium cromoglycate (DSCG) nasal spray, one puff per nostril, four times daily, for 3 weeks
Number of subjects: 66
Study 8560162 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-aspartyl-glutamic acid (NAAGA) nasal spray
Number of subjects: 66
Study 8560162 — intervention group
Group type: COMPARATOR
Intervention: Disodium cromoglycate (DSCG) nasal spray
Number of subjects: 66
Study 2672925 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiprilose HCl, 6 g/d
Number of subjects: 201
Study 2672925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 31923797 — intervention group
Group type: EXPERIMENTAL
Intervention: Text-delivered counseling for cannabis use disorder
Number of subjects: 96
Study 30747908 — intervention group
Group type: EXPERIMENTAL
Intervention: NKTR-181 100 to 400 mg every 12 hours
Number of subjects: 610
Study 30747908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 610
Study 30747908 — intervention group
Group type: EXPERIMENTAL
Intervention: NKTR-181
Number of subjects: 610
Study 28420906 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound plus nerve stimulator guidance
Number of subjects: 60
Study 28420906 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound guidance only
Number of subjects: 60
Study 27176755 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 750
Study 27176755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 750
Study 25064487 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand massage therapy
Number of subjects: 40
Study 25064487 — intervention group
Group type: COMPARATOR
Intervention: Control group (no massage)
Number of subjects: 40
Study 22130790 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical formulation of griseofulvin with TPGS and ethanol
Number of subjects: 0
Study 22130790 — intervention group
Group type: COMPARATOR
Intervention: Topical formulation of griseofulvin
Number of subjects: 0
Study 19394033 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rehydration solution plus racecadotril (OR + R)
Number of subjects: 189
Study 19394033 — intervention group
Group type: COMPARATOR
Intervention: Oral rehydration solution (OR)
Number of subjects: 189
Study 17136505 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-alanine (CarnoSyn)
Number of subjects: 22
Study 17136505 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 22
Study 15151947 — intervention group
Group type: EXPERIMENTAL
Intervention: SRL172 (killed Mycobacterium vaccae) with chemotherapy
Number of subjects: 419
Study 15151947 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 419
Study 12593029 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 49
Study 12593029 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (cefotaxime, ceftriaxone, amoxicillin/clavulanate)
Number of subjects: 49
Study 9649142 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin 75 mg/m² i.v. every 3 weeks
Number of subjects: 232